SCHEMBL20135058

SCHEMBL20135058

Cc1cnc(N2CCN(C(=O)c3ccc(C4(C5CCOCC5)NC(=O)NC4=O)cc3)CC2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.37
ADAMTS5 Q9UNA0 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ABL1 P00519 2/20 0.35
BCR P11274 1/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 3/20 0.35
KMT2A Q03164 2/20 0.35
RAB9A P51151 1/20 0.35
TP53 P04637 1/20 0.34
THRB P10828 1/20 0.34
REV1 Q9UBZ9 1/20 0.34
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688853 1.00 ADAM17 (0.37) ADAM17ADAMTS5ALDH1A1ABL1BCR
SCHEMBL29688749 0.94 ADAMTS5 (0.40) ADAM17ADAMTS5ALDH1A1KDM4EKMT2A
SCHEMBL20135181 0.94 ADAMTS5 (0.40) ADAM17ADAMTS5ALDH1A1KDM4EKMT2A
SCHEMBL29688916 0.92 ALDH1A1 (0.38) ADAM17ADAMTS5ALDH1A1KDM4EMAPT
SCHEMBL20135135 0.92 ALDH1A1 (0.38) ADAM17ADAMTS5ALDH1A1KDM4EMAPT
SCHEMBL29688558 0.91 ADAM17 (0.36) ADAM17ADAMTS5ALDH1A1ABL1BCR
SCHEMBL20134804 0.91 ADAM17 (0.36) ADAM17ADAMTS5ALDH1A1ABL1BCR
SCHEMBL20134997 0.87 ADAMTS5 (0.38) ADAM17ADAMTS5ALDH1A1ABL1BCR
SCHEMBL20135138 0.85 SLC6A7 (0.37) ADAM17ADAMTS5ALDH1A1KDM4E
SCHEMBL29688969 0.85 SLC6A7 (0.37) ADAM17ADAMTS5ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAM17 36/4885ADAMTS5 23/4885ALDH1A1 584/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAM17 39/4885ADAMTS5 25/4885ALDH1A1 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.